Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

Autor: Inja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, Tapan K Nayak, Linda Fahrni, Ralf J. Hosse, Danny Gerrits, Edwin J. W. Geven, Johannes Sam, Sabine Lang, Esther Bommer, Virginie Steinhart, Elisabeth Husar, Sara Colombetti, Erwin Van Puijenbroek, Markus Neubauer, J. Mark Cline, Pradeep K. Garg, Gregory Dugan, Federica Cavallo, Gonzalo Acuna, Jehad Charo, Volker Teichgräber, Stefan Evers, Otto C. Boerman, Marina Bacac, Ekkehard Moessner, Pablo Umaña, Christian Klein

Publikováno v: mAbs, Vol 13, Iss 1 (2021)

Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα. Here,

Externí odkaz: https://doaj.org/article/92299c28b9d34a45bf95cf39c2bbc494

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

Autor: Ralf Hosse, Federica Cavallo, Esther Bommer, Danny Gerrits, Valeria Gonzalez-Nicolini, Marina Bacac, Volker Teichgräber, Stefan Evers, Gregory O. Dugan, Tapan K. Nayak, Erwin van Puijenbroek, Inja Waldhauer, Elisabeth Husar, J. Mark Cline, Virginie Steinhart, Gonzalo Acuna, Ekkehard Moessner, Markus Neubauer, Johannes Sam, Edwin J. W. Geven, Pradeep Garg, Sabine Lang, Jehad Charo, Sara Colombetti, Christian Klein, Linda Fahrni, Anne Freimoser-Grundschober, Otto C. Boerman, Pablo Umana

Publikováno v: mAbs
article-version (VoR) Version of Record
Mabs, 13
Mabs, 13, 1

Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα. Here,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54fe9bb5153efb5907c70c2cecf1c903
https://pubmed.ncbi.nlm.nih.gov/33974508

Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases

Autor: Edwin E. G. W. ter Voert, Wim J.G. Oyen, Peter Laverman, Arend Heerschap, Ralph Sinkus, Linda Heijmen, Donna Michelle Smith, Janneke D.M. Molkenboer-Kuenen, John R. Griffiths, Otto C. Boerman, Danny Gerrits, Davina J. Honess, Sabrina Doblas, Sandra Heskamp, Kathrin Heinzmann

Publikováno v: Molecular Imaging and Biology, 19, 4, pp. 540-549
ResearcherID
Heskamp, S, Heijmen, L, Gerrits, D, Molkenboer-Kuenen, J D M, Ter Voert, E G W, Heinzmann, K, Honess, D J, Smith, D M, Griffiths, J R, Doblas, S, Sinkus, R, Laverman, P, Oyen, W J G, Heerschap, A & Boerman, O C 2016, ' Response Monitoring with [ 18 F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases ', Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, pp. 1-10 . https://doi.org/10.1007/s11307-016-1021-2
Molecular Imaging and Biology, 19, 540-549

Purpose: The aim of the study was to investigate the potential of diffusion-weighted magnetic resonance imaging (DW-MRI) and 3′-dexoy-3′-[18F]fluorothymidine ([18F]FLT) positron emission tomography (PET) as early biomarkers of treatment response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f71eae15d2c19e3c70be4f21d77336c
https://hdl.handle.net/2066/177924

Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors

Autor: Susanne Lütje, Ken Herrmann, Janneke D.M. Molkenboer-Kuenen, Sandra Heskamp, Otto C. Boerman, Giulio Fracasso, Danny Gerrits, Marco Colombatti

Publikováno v: The Journal of Nuclear Medicine (1978), 59, 494-501
The Journal of Nuclear Medicine (1978), 59, 3, pp. 494-501

Prostate cancer (PCa) is the most common cancer in men worldwide. In general, PCa responds poorly to chemotherapy. Therefore, antibody-drug conjugates (ADCs) have been developed to specifically deliver highly cytotoxic drugs to the tumor. Because the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7d05ce254ef76a296b003904383e963
http://hdl.handle.net/2066/189764

Can 111In-RGD2 Monitor Response to Therapy in Head and Neck Tumor Xenografts?

Autor: Gerben M. Franssen, Danny Gerrits, Samantha Y.A. Terry, Wim J.G. Oyen, Otto C. Boerman, Jasper Lok, Keelara Abiraj

Publikováno v: The Journal of Nuclear Medicine (1978), 55, pp. 1849-1855
The Journal of Nuclear Medicine (1978), 55, 1849-1855

Item does not contain fulltext RGD (arginylglycylaspartic acid)-based imaging tracers allow specific imaging of integrin αvβ3 expression, proteins overexpressed during angiogenesis; however, few studies have investigated the potential of these trac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c25994a7548ca28a80635c4b93b58f
https://hdl.handle.net/2066/170660